Manus

ASPR supports onshoring and domestic manufacturing. During a recent site visit to one facility, @manusbio GA facility, Congressional staff saw: ✅The site where key components of an influenza antiviral will be produced. ✅Ongoing domestic production of key starting materials for an anti-malaria drug. ✅Decreased dependence on foreign pharmaceutical supply chains. ✅More jobs for Americans. Learn more about ASPR's program to make essential medicines here at home under the Defense Production Act Title III Program: aspr.hhs.gov/legal/DPA/Page…

Over 80% of key ingredients in U.S. medicines are sourced overseas. Today, we’re expanding our partnership with @HHSgov to boost U.S. production of shikimic acid – a key starting material for oseltamivir, the active ingredient in Tamiflu – helping strengthen domestic supply and reduce flu-season shortages of oseltamivir. Read more: manusbio.com/articles/manus… #NationalSecurity #MadeInAmerica #Onshoring #SupplyChain

We’re counting down to #IFTFirst 2025 in Chicago! In just a few days, the Manus team will be at booth #S1265, ready to share our summer-ready, sugar-free treats and #sustainable, supply-secure citrus BioIngredients, Made by Manus™. Learn more: manusbio.com/articles/manus…

Heading to #IFTFirst 2025 next week in Chicago? Let’s connect! Manus will be at Booth #S1265 at the largest global #foodscience and innovation expo, hosted by @IFT. See you there!

Industrial biotech, built to scale. This week, Manus and @InscriptaInc united to form a new leader in biomanufacturing — delivering real-world impact through scalable bioalternatives. Made to scale. Made to deliver. Made by Manus™ manusbio.com/articles/manus…

We are excited to announce that Manus has received a $32.4 million award from the @HHSGov Defense Production Act Title III Program to support the domestic production of critical essential medicines at population-scale: manusbio.com/articles/manus… #biotechnology #biomanufacturing

We are excited to announce a strategic partnership, The Natural Sweetener Alliance, with @tateandlyleplc to expand access to natural sugar reduction solutions. Learn more about stevia Reb M, the first jointly introduced ingredient, and this partnership: bit.ly/40nGYcF

Last week, Manus VP of R&D, Joe Shaw, spoke at SIMB 2024. He touched on key insights and core principles behind Manus’ approach to strain design and metabolic engineering to optimize cell factories using Manus' BioOptimization Cycle™ technology: manusbio.com/science-and-te…

Manus CTO, Christine Santos, explains our BioManufacturing Program in-depth and how it can help companies make bioalternatives at scale, enabling them to expand their scale-up and production capacity using our state-of-the-art BioFacility in Augusta: bit.ly/4bYbDAl.

The Manus team is excited to attend the @TheBioMADE 2024 Member Meeting on May 29-31 in Minneapolis, MN. This exciting conference brings together BioMADE members and the U.S. Government to participate in member discussions about the latest trends in technology and more!

While we are busy accelerating the transition to bioalternatives, we took a moment to enjoy time with our amazing team of BioHands, the beautiful weather in Augusta, and some free ice cream! #bioeconomy #biomanufacturing #biotechnology #syntheticbiology #MadeByManus

Join Manus next week as we take you behind the scenes of @SynBioBeta 2024. We’ll be connecting with key players in the industry to discuss bioalternatives and how we deliver the benefits of synthetic biology by bridging the Valley of Death between lab scale and manufacturing.

Chief Technology Officer at Manus, Christine Santos, recently sat down with @SynBioBeta to discuss the potential benefits of bioalternatives, the future of synthetic biology, and how our BioManufacturing Program is helping address industry challenges: bit.ly/3U8GCSE

#EarthDay is a powerful reminder that our planet needs us to fight for real, achievable sustainability practices across all industries. We’d love to hear about how your company or industry could benefit from bioalternatives– comment below!

Manus CTO, Christine Santos, spoke with @SynBioBeta about the future of bioalternatives: bit.ly/3U3EGKZ At Manus, we engineer bioalternatives to replicate nature, creating cost-effective, reliable, and sustainable molecules for use in everyday products.

To change the #syntheticbiology industry takes purpose, commitment, and an unwavering drive to challenge the status quo. That’s what our new Chief Business Officer, David Muldoon, brings to the table, along with more than 25 years of deep industry and value chain experience.

Join Waleed Nasser and David Tennenhouse from the @NSF as they discuss their $80 million in funding opportunities that support endeavors specifically aimed at growing the U.S. #bioeconomy. Register now: synbiobeta.zoom.us/webinar/regist… #bioeconomy #syntheticbiology @SynBioBeta

At Manus, we are accelerating the transition to bioalternatives by delivering the benefits of synthetic biology, today. We're excited to share our vision and expand the possibilities with our customers, partners, and industry peers through our new site: manusbio.com

Innovation requires both an understanding of what’s come before and the courage to change it. 2024 is a big year for bioalternatives. We invite you to join the transition with us. Stay tuned for more. #biomanufacturing #biotechnology #syntheticbiology #MadeByManus